ID   HCC827-GR-high2
AC   CVCL_S704
DR   cancercelllines; CVCL_S704
DR   Cosmic; 1896427
DR   Wikidata; Q54881801
RX   PubMed=23542356;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Iressa).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2063 ! HCC827
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 15
//
RX   PubMed=23542356; DOI=10.1158/0008-5472.CAN-12-4136;
RA   Shien K., Toyooka S., Yamamoto H., Soh J., Jida M., Thu K.L.,
RA   Hashida S., Maki Y., Ichihara E., Asano H., Tsukuda K., Takigawa N.,
RA   Kiura K., Gazdar A.F., Lam W.L., Miyoshi S.;
RT   "Acquired resistance to EGFR inhibitors is associated with a
RT   manifestation of stem cell-like properties in cancer cells.";
RL   Cancer Res. 73:3051-3061(2013).
//